Isofol Medical

The information in the press release is intended for investors.

For further information, please contact

Isofol Medical AB (publ)
Thomas Andersson, Chief Executive Officer  
E-mail: thomas.andersson@isofolmedical.com
Phone: +46 (0) 709 44 00 93

Roy Jonebrant, Chief Financial Officer 
E-mail: roy.jonebrant@isofolmedical.com
Phone: +46 (0) 708 48 12 36

This information is information that Isofol Medical AB (publ) is obliged to make public pursuant to the Securities Markets Act. The information was submitted for publication, through the agency of the contact persons set out above, at 09:00 CEST on April 6, 2023.

About Isofol Medical AB (publ) 

Isofol Medical AB (publ) is developing the drug candidate arfolitixorin with the aim of increasing the efficacy of current standard treatments for colorectal cancer and certain other tumor diseases. A Phase III study of arfolitixorin has been completed and the company is now evaluating opportunities to advance the drug candidate toward a marketing authorization application by conducting additional studies and entering potential partnerships. Isofol Medical AB (publ) is traded on Nasdaq Stockholm.

www.isofolmedical.com